Atrial Fibrillation Market Size, Company Revenue Share, Key Drivers & Trend Analysis, 2030

Posted by sneha j on October 3rd, 2022

Atrial fibrillation is a type of irregular heartbeat characterized by rapid and irregular beating. Blood may clot and congest in the atria at the same time because of insufficient blood received by ventricles. These clots can enter the circulation and reach the brain, causing stroke. The transmission of electrical impulses to the lower heart chambers is disrupted in atrial fibrillation, which causes a rapid, slow, or irregular heartbeat. During atrial fibrillation, upper chamber and lower chamber of the heart beat irregularly, chaotically, and out of sync, which causes shortness of breath, chest pain, weakness, ad lightheadedness or fainting. 

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭

Numerous technical improvements in the treatment and diagnostics of atrial fibrillation, as well as the rise in prevalence of atrial fibrillation in the senior population, are major drivers of atrial fibrillation industry. However, market expansion is hampered by problems, such as strict government laws, expensive treatment costs for atrial fibrillation, and shortage of experienced specialists and technicians.

Key players focus on expanding their portfolio by introducing technologically developed products, which re expected to help reduce the risk of stroke and atrial fibrillation in patients. For instance, in April 2021, ArtiCure, Inc., a major pioneer in atrial fibrillation (Afib) therapy introduced Epi-Sense System, which is approved by the U.S. Food & Drug Administration (FDA). Epi-Sense System is used to treat patients with long-standing persistent cardiac arrhythmias or atrial fibrillation.

However, during the COVID-19 pandemic lockdown, various manufacturers in the atrial fibrillation market had to stop their business in countries, such as China, the U.S., and India, which negatively affected the atrial fibrillation market growth. This break directly impacted the sales and decline in atrial fibrillation market share. In addition, lack of manpower and raw materials also constricted supply of equipment of atrial fibrillation, which negatively influenced the growth of the market. However, reopening of production facilities and introduction of vaccines for COVID-19 are anticipated to lead to re-opening of atrial fibrillation companies.

𝗚𝗲𝘁 𝗗𝗲𝘁𝗮𝗶𝗹𝗲𝗱 𝐑𝐞𝐩𝐨𝐫𝐭

Like it? Share it!

sneha j

About the Author

sneha j
Joined: July 12th, 2022
Articles Posted: 104

More by this author